News & Views
Funding Takes Therapy to Clinical Stage Planning
Mar 04 2020
SBRI Healthcare, the NHS England funded initiative championed by the Academic Health Science Network (AHSN), has awarded Mogrify$1.1M of Phase II funding to assess its regenerative cartilage therapy for the treatment of cartilage defects, osteoarthritis and other musculoskeletal conditions, before entering clinical trials. Phase I funding earlier this year enable the company to identify the transcription factors and culture conditions required to convert various cell types into healthy mature chondrocytes, through use of its data-driven direct cellular conversion technology.
Dr Karin Schmitt, CBO, Mogrify, said: “We select projects strategically based on both commercial and scientific considerations and are delighted with the progress of this collaboration with Dr Wael Kafienah’s laboratory at the University of Bristol. The continued support for our lead musculoskeletal asset from SBRI Healthcare has not only allowed us to reach this phase but will enable us to carry the chondrocyte conversions through to the next stage.”
Pierre-Louis Joffrin, Corporate Development Executive, Mogrify, said: “Osteoarthritis is the most common joint disorder and with current treatments focused only on addressing the symptoms, there is a huge unmet medical need. Through this additional funding from the NHS England initiative, we will be able to take the project through the efficacy and safety studies necessary to see it make a difference to patients as we now start planning for the clinical stages of the development.”
Digital Edition
Lab Asia 31.6 Dec 2024
December 2024
Chromatography Articles - Sustainable chromatography: Embracing software for greener methods Mass Spectrometry & Spectroscopy Articles - Solving industry challenges for phosphorus containi...
View all digital editions
Events
Jan 22 2025 Tokyo, Japan
Jan 22 2025 Birmingham, UK
Jan 25 2025 San Diego, CA, USA
Jan 27 2025 Dubai, UAE
Jan 29 2025 Tokyo, Japan